Drug Development Phase: 1B
Kineta’s lead clinical stage autoimmune candidate, Dalazatide (formerly ShK-186), is a first-in-class drug candidate that aims to selectively target autoimmune disease-causing cells while leaving the patient’s protective immune response unaffected.
Dalazatide is a synthetic analog of a peptide isolated from a Caribbean sea anemone. It is a potent inhibitor of the Kv1.3 potassium channel and an important new pharmaceutical target due to its expression on effector memory T-cells. Effector memory T-cells are a subset of the T-cell family that cause inflammation and tissue damage in a broad range of autoimmune diseases. Dalazatide blocks activation of these cells without suppressing other T cell subtypes, potentially leaving intact the innate immune response and a majority of the adaptive immune response. As a result, dalazatide may not cause broad immune suppression in treated patients.
Dalazatide is being studied as a potential treatment for multiple autoimmune diseases including lupus, psoriasis, psoriatic arthritis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases, type 1 diabetes mellitus, atopic dermatitis, asthma, ANCA vasculitis and autoimmune uveitis.
Kineta is the first company to bring a Kv1.3 inhibitor into human clinical trials and has conducted two previous safety and tolerability studies of dalazatide in healthy volunteers. Additionally, dalazatide demonstrated clinical proof-of-concept in a Phase 1b Psoriasis Trial and is now ready for Phase II development. See Phase IB clinical trial results.
Dalazatide is administered via subcutaneous injection twice a week. Kineta is developing a sustained release formulation that may be administered as infrequently as every 3 months. Kineta’s Kv1.3 targeting franchise provides multiple dosing options including a subcutaneous autoinjector, subcutaneous depot, eye drop, and topical cream.
Dalazatide is jointly developed by Kineta and its sister corporation KPI Therapeutics Inc.